These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 26246396)

  • 21. Diagnosis of equine pituitary pars intermedia dysfunction.
    Stewart AJ; Ireland JL; Durham AE; McGowan CM
    Vet J; 2023; 300-302():106036. PubMed ID: 37805159
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of pituitary pars intermedia dysfunction and Prascend (pergolide tablets) treatment on endocrine and immune function in horses.
    Miller AB; Loynachan AT; Bush HM; Hart KA; Barker VD; Campana-Emard AG; Grubbs ST; Adams AA
    Domest Anim Endocrinol; 2021 Jan; 74():106531. PubMed ID: 32942194
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of basal plasma α-melanocyte-stimulating hormone and adrenocorticotrophic hormone concentrations for the diagnosis of pituitary pars intermedia dysfunction from a population of aged horses.
    Mc Gowan TW; Pinchbeck GP; Mc Gowan CM
    Equine Vet J; 2013 Jan; 45(1):66-73. PubMed ID: 22563728
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Equine pituitary pars intermedia dysfunction: current understanding and recommendations from the Australian and New Zealand Equine Endocrine Group.
    Secombe CJ; Bailey SR; de Laat MA; Hughes KJ; Stewart AJ; Sonis JM; Tan R
    Aust Vet J; 2018 Jul; 96(7):233-242. PubMed ID: 29862508
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of blue light therapy on plasma adrenocorticotropic hormone (ACTH) and hypertrichosis in horses with pituitary pars intermedia dysfunction.
    Miller AB; Murphy BA; Adams AA
    Domest Anim Endocrinol; 2022 Jan; 78():106651. PubMed ID: 34656964
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Association of season and pasture grazing with blood hormone and metabolite concentrations in horses with presumed pituitary pars intermedia dysfunction.
    Frank N; Elliott SB; Chameroy KA; Tóth F; Chumbler NS; McClamroch R
    J Vet Intern Med; 2010; 24(5):1167-75. PubMed ID: 20666984
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fecal strongyle egg counts in horses with suspected pre-clinical pituitary pars intermedia dysfunction before and after treatment with pergolide.
    Christen G; Gerber V; van der Kolk JH; Frey CF; Fouché N
    Vet J; 2018 May; 235():60-62. PubMed ID: 29704940
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of seasonal influences on adrenocorticotropic hormone response to the thyrotropin-releasing hormone stimulation test and its accuracy for diagnosis of pituitary pars intermedia dysfunction.
    Adams AA; Siard-Altman MH; Reedy SE; Barker D; Elzinga S; Sanz MG; Urschel K; Ireland JL
    Vet J; 2023; 300-302():106035. PubMed ID: 37802466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of suspected pituitary pars intermedia dysfunction in horses with laminitis.
    Donaldson MT; Jorgensen AJ; Beech J
    J Am Vet Med Assoc; 2004 Apr; 224(7):1123-7. PubMed ID: 15074858
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Initial analytic quality assessment and method comparison of an immunoassay for adrenocorticotropic hormone measurement in equine samples.
    Irvine KL; Burt K; Hill AJ; Shaw S; Papasouliotis K
    Vet Clin Pathol; 2016 Mar; 45(1):154-63. PubMed ID: 26756538
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Plasma fructosamine concentrations in horses with pituitary pars intermedia dysfunction with and without laminitis.
    Knowles EJ; Menzies-Gow NJ; Mair TS
    Equine Vet J; 2014 Mar; 46(2):249-51. PubMed ID: 23663105
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Clinical implications of using adrenocorticotropic hormone diagnostic cutoffs or reference intervals to diagnose pituitary pars intermedia dysfunction in mature horses.
    Horn R; Stewart AJ; Jackson KV; Dryburgh EL; Medina-Torres CE; Bertin FR
    J Vet Intern Med; 2021 Jan; 35(1):560-570. PubMed ID: 33368633
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical implications of imprecise sampling time for 10- and 30-min thyrotropin-releasing hormone stimulation tests in horses.
    Vorster DM; Wang W; Kemp KL; Bamford NJ; Bertin FR
    Equine Vet J; 2024 Mar; 56(2):291-298. PubMed ID: 37649416
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Repeatability of a thyrotropin-releasing hormone stimulation test for diagnosis of pituitary pars intermedia dysfunction in mature horses.
    Kam YN; McKenzie K; Coyle M; Bertin FR
    J Vet Intern Med; 2021 Nov; 35(6):2885-2890. PubMed ID: 34642962
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Relationships of inflamm-aging with circulating nutrient levels, body composition, age, and pituitary pars intermedia dysfunction in a senior horse population.
    Siard-Altman MH; Harris PA; Moffett-Krotky AD; Ireland JL; Betancourt A; Barker VD; McMurry KE; Reedy SE; Adams AA
    Vet Immunol Immunopathol; 2020 Mar; 221():110013. PubMed ID: 32058159
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Equine pituitary pars intermedia dysfunction.
    McFarlane D
    Vet Clin North Am Equine Pract; 2011 Apr; 27(1):93-113. PubMed ID: 21392656
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neutrophil function in healthy aged horses and horses with pituitary dysfunction.
    McFarlane D; Hill K; Anton J
    Vet Immunol Immunopathol; 2015 Jun; 165(3-4):99-106. PubMed ID: 25962580
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Measurement of cortisol concentration in the tears of horses and ponies with pituitary pars intermedia dysfunction.
    Hart KA; Kitchings KM; Kimura S; Norton NA; Myrna KE
    Am J Vet Res; 2016 Nov; 77(11):1236-1244. PubMed ID: 27805438
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic and pharmacodynamic properties of pergolide mesylate following long-term administration to horses with pituitary pars intermedia dysfunction.
    McFarlane D; Banse H; Knych HK; Maxwell LK
    J Vet Pharmacol Ther; 2017 Apr; 40(2):158-164. PubMed ID: 27301465
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Systemic and pituitary pars intermedia antioxidant capacity associated with pars intermedia oxidative stress and dysfunction in horses.
    McFarlane D; Cribb AE
    Am J Vet Res; 2005 Dec; 66(12):2065-72. PubMed ID: 16379648
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.